On December 22, 2023, ALX Oncology Holdings Inc. and its indirectly wholly-owned subsidiary, ALX Oncology Inc. entered into the Third Amendment to Loan and Security Agreement by and among the Company as a guarantor, the Borrower, Oxford Finance LLC, as collateral agent, and the lenders party thereto. The Third Amendment amends the Loan Agreement, dated as of October 27, 2022, among Agent, the lenders party thereto (the Lenders), Borrower, Holdings and the other guarantors party thereto. The Third Amendment amends the Loan Agreement to, among other things, (i) extend the draw period for the Term A Loans from December 31, 2023 to June 30, 2024, (ii) as a condition for the funding of any Term A Loans after the effective date of the Third Amendment, require that the Phase 2 portion of the ASPEN-06 study in gastric/gastroesophageal junction cancer either remains ongoing or the achievement of a milestone related to the development of the ASPEN-06 study, and (iii) include a contingency fee in the amount of $600,000 payable to the Lenders, in accordance with their pro rata shares, if Borrower prepays any of the loans under the Loan Agreement other than in connection with a refinancing of the Loan Agreement with the Lenders and their affiliates.